Agents targeted to the mammalian target of rapamycin (mTOR), which is associated with increased angiogenesis by binding to intracellular protein (FKBP-12) 8, are associated with fatigue, rash, anemia, and metabolic abnormalities 9,10. Here, MTOR is linked to anemia.